VJOncology is committed to improving our service to you

ASCO 2020 | PRADO: personalized response-driven surgery and adjuvant therapy in stage III melanoma

VJOncology is committed to improving our service to you

Sunandana Chandra

Sunandana Chandra, MD, MS, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, reviews data reported from the PRADO study (NCT02977052). This phase II study investigated personalized response-driven surgery and adjuvant therapy following neoadjuvant ipilimumab and nivolumab in patients with resectable stage III melanoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter